Published October 2013 | Version v1
Journal article

Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma

  • 1. Cancer Center Karolinska, Karolinska University Hospital, Stockholm (Sweden)
  • 2. Department of Oncology–Pathology, Karolinska Institutet, Stockholm (Sweden)
  • 3. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala (Sweden)
  • 4. Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford (United Kingdom)
  • 5. Biodonstia Research Institute, San Sebastián (Spain)
  • 6. Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala (Sweden)

Description

Deregulation of microRNA (miRNA) expression has been documented in diffuse large B-cell lymphoma (DLBCL). However, the impact of miRNAs and their machinery in DLBCL is not fully determined. Here, we assessed the role of miRNA expression and their processing genes in DLBCL development. Using microarray and RT-qPCR approaches, we quantified global miRNAs and core components of miRNA-processing genes expression in 75 DLBCLs (56 de novo and 19 transformed) and 10 lymph nodes (LN). Differential miRNA signatures were identified between DLBCLs and LNs, or between the de novo and transformed DLBCLs. We also identified subsets of miRNAs associated with germinal center B-cell phenotype, BCL6 and IRF4 expression, and clinical staging. In addition, we showed a significant over-expression of TARBP2 in de novo DLBCLs as compared with LNs, and decreased expression of DROSHA, DICER, TARBP2 and PACT in transformed as compared with de novo cases. Interestingly, cases with high TARBP2 and DROSHA expression had a poorer chemotherapy response. We further showed that TARBP2 can regulate miRNA-processing efficiency in DLBCLs, and its expression inhibition decreases cell growth and increases apoptosis in DLBCL cell lines. Our findings provide new insights for the understanding of miRNAs and its machinery in DLBCL

Availability note (English)

Available from http://dx.doi.org/10.1038/bcj.2013.49; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816210

Additional details

Publishing Information

Journal Title
Blood Cancer Journal
Journal Volume
3
Journal Issue
10
Journal Page Range
p. 152
ISSN
2044-5385

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46049350
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
APOPTOSIS; CHEMOTHERAPY; DEREGULATION; EFFICIENCY; GENES; GROWTH; INHIBITION; LYMPH NODES; LYMPHOMAS; PATHOGENESIS; PHENOTYPE
Descriptors DEC
DISEASES; IMMUNE SYSTEM DISEASES; LYMPHATIC SYSTEM; MEDICINE; NEOPLASMS; THERAPY

Optional Information

Copyright
Copyright (c) 2013 Macmillan Publishers Limited
Notes
PMCID: PMC3816210; PMID: 24121164; OAI: oai:pubmedcentral.nih.gov:3816210